Background: Metabolic dysfunction is a hallmark of differential aging, specifically in African Americans. Investigation of systemic metabolic state, multiorgan aging, and long-term cardiovascular outcome in African Americans has not been reported. Methods: We studied 291 African American males in the Health, Aging, and Body Composition (Health ABC) study to identify circulating metabolites related to the Newman healthy aging index (HAI; a multiparametric score comprised of blood pressure, blood glucose, neurocognitive function, creatinine, and forced vital capacity). We examined the relationship of selected metabolites differential abundant at the extremes of HAI with long-term survival from cardiovascular mortality. Results: The median age was 73 years. We identified 19 metabolites differentially expressed in blood in 86 study participants at the extremes of HAI (HAI 0-3: N = 30 vs 8-10: N = 56). At a median follow-up of 10 years, 78 participants (27 per cent) died from cardiovascular causes. After adjustment for age, body mass index, presence of prevalent cardiovascular disease, creatinine, and HAI, six of these 19 metabolites were associated with long-term cardiovascular mortality. Although several metabolites had been previously reported in Caucasians (eg, isocitrate), we identified several metabolites with unreported association with cardiac disease. Metabolites associated with HAI and cardiac death in African Americans specified pathways relevant to nitric oxide, oxidative stress, mitochondrial function, urea cycle, and gut microbial metabolism. Conclusions: Metabolite profiling in African Americans identified known and novel metabolic pathways linked to HAI and cardiovascular death. Further investigation in larger patient cohorts is required to uncover race-based signatures of cardiovascular disease with aging.
The prevalence of "unhealthy" aging is greater in African Americans at the same age relative to other ethnicities (1) . Differences in metabolism-a central component of age-related decline-may be an important determinant of cardiovascular prognosis, especially in African Americans (2) . Metabolite profiling interrogates systemswide cardiometabolic function quantitatively (3), although how dysfunction in specific metabolic pathways is associated with cardiovascular morbidity in aging African Americans is not well understood. Previous work in the Health, Aging, and Body Composition (Health ABC) study has identified metabolites associated with body composition (4) . Here, we address a different question in aging by quantifying circulating metabolites in the same subsample of older African American men to identify metabolites associated with a multiparametric index of healthy aging (the healthy aging index, HAI) (1) . We hypothesize that the extremes of HAI will be associated with distinct metabolite profiles, and these metabolites may identify individuals at high-risk for long-term cardiovascularrelated mortality.
Methods
Health ABC recruited 3075 African American and Caucasian American men and women between 70-79 years from two sites with previously described methods (5) . From 319 African American men selected at random from the overall population for metabolite profiling at the Year 2 visit (1998-1999) (4), our analytic sample consisted of 291 individuals with overlap between metabolites at Year 2 and HAI quantified at Year 1 (1997 Year 1 ( -1998 . Metabolite profiling was performed at the Broad Institute (Cambridge, MA) as published previously (4). In brief, three different liquid chromatography-mass spectroscopic (LC-MS) methodologies were employed to quantify 350 polar and lipid metabolites in circulating plasma (that had not been previously freeze-thawed); a full reference for methods in our laboratory has been previously published (for lipids, hydrophilic interaction liquid chromatography analyses of water-soluble metabolites in positive and negative modes) (4) . For the purposes of this analysis, metabolites that could not be measured in a given participant were assigned 50 per cent the minimum value of the metabolite, as in prior work (4) . We included 341 out of 350 metabolites in our analysis (nine metabolites with expression in <50 per cent of subjects across all 291 excluded; Supplementary Table 1) .
We derived a metabolite profile associated with the HAI, a multiorgan index with two points each for five domains (systolic blood pressure, forced lung vital capacity, creatinine, modified minimental status score, and fasting glucose) (1), yielding a score between 0 and 10 (greater values corresponding to more disease). Given that domains of HAI were assessed at study entry (not at second study visit), we used HAI at baseline for analyses. All metabolites were log-transformed for differential expression. We performed differential expression analysis to compare subjects at the extremes of HAI: high HAI (unhealthy; 8-10) and low HAI (healthy; 0-3) using the LIMMA package in R that enables linear models to be fitted to multifactor-designed experiments. Conventional t-tests calculate the variance from each gene, whereas the moderated t-test in LIMMA (6, 7) uses an empirical Bayes approach that shrinks the estimated sample variances toward a pooled estimate, resulting in a more reliable differential expression analysis when the number of samples is small. Although the LIMMA package was introduced to perform differential expression analyses for microarray experiments (8) , it is also used routinely in other applications of high-dimensional data (9), including metabolomics (10) . The extremes of HAI were selected based on visual identification of the tails of the HAI distribution ( Figure 1A ). We used a Benjamini-Hochberg false-discovery rate (FDR) of 0.05 to limit type 1 error.
We estimated Cox models for cardiovascular disease (CVD) mortality in 290 individuals with at least one day of follow-up after metabolite analysis as a function of metabolites that were differentially expressed at the extremes of HAI. Death was adjudicated by committee through September 2014 via use of medical records, death certificate, and informant interviews. CVD mortality included death from coronary heart disease, cerebrovascular disease, other atherosclerotic cardiovascular disease (eg, aneurysm), or other nonatherosclerotic cardiovascular diseases (eg, valvular disease). Briefly, if a participant or proxy was unable to attend an in-person study visit, a phone interview was conducted with either the participant or the proxy. Subsequently, if neither of the above was possible, obituaries and national death index were searched. If no contact was made and no death record found was found, the participant was considered to be lost to follow-up as of the day after the last contact.
We constructed three sets of models: (a) univariable models for metabolite-CVD mortality association (not accounting for competing risk of non-CVD mortality); (b) univariable models as in #1, but accounting for competing risk (using Fine-Gray models implemented in SAS macro PSHREG (11)); (c) multivariable models (accounting for confounding and competing risk) that were adjusted for age, BMI, presence of prevalent CVD, and creatinine (by metabolite profiling at Year 2), and HAI at baseline. The multivariable models (#3) were constructed for those metabolites that passed an FDR threshold of 5 per cent in both models #1 and #2. Univariable Cox models were estimated in 290 participants; of this group, multivariable Cox models were estimated in 280 participants (10 missing prevalent CVD adjudication). Proportional hazards were assessed in univariable Cox models (without competing risk) via a supremum test. We used SAS version 9.3 (SAS Institute, Cary, NC) or R 3.3.3 (R project, www.r-project.org). A two-tailed p < .05 (with appropriate FDR correction, wherever relevant) was considered statistically significant.
Results
Characteristics of our population are shown in Table 1 . The median HAI was 6 (IQR 4-7), with a median age of 73 years (IQR 71-76 years). Median body mass index was 27.0 kg/m 2 (IQR 24.2-30.0) and median creatinine was 1.20 mg/dL (1.10-1.30). We identified extremes of HAI based on visual inspection of the distribution (Supplementary Figure 1) . We identified 19 metabolites differentially abundant between the "healthy" (0-3; N = 30) and "unhealthy" HAI group (8) (9) (10) ; N = 56), with a higher level of each metabolite in individuals in the high (unhealthy) HAI group. Boxplots of the 19 differentially expressed metabolites between the "healthy" and "unhealthy" extremes of HAI are shown in Figure 1 . In addition, in To assess the potential prognostic value of the 19 metabolites associated with extremes of HAI, we constructed three sets of Cox proportional models for the association of each metabolite with long-term CVD mortality, with and without competing risks (Table 2) . From the 290 participants included in Cox analysis, 78 participants (27 per cent) experienced CVD mortality (median follow-up of 10.0 years after date of metabolite collection, interquartile range 5.2-14.9 years; 140 experienced noncardiovascular mortality, and 72 individuals were censored). We observed several HAIrelated metabolites associated with CVD mortality with and without competing risks accounted and after an FDR correction, including isocitrate, glucuronate, 5-aminolevulinic acid, N-carbamoyl betaalanine, symmetric dimethylarginine (SDMA), and trimethylamine N-oxide (Table 2 ). After multivariable adjustment and competing risks accounted, two metabolites-glucuronate and symmetric dimethylarginine (SDMA)-were significant. Metabolites associated with HAI and CVD mortality specified pathways relevant to nitric oxide, oxidative stress, mitochondrial function, urea cycle, and gut microbial metabolism (Table 3) .
Discussion
Here, we identified 19 metabolites associated with extremes of HAI in African American males, involved in a variety of pathways with potential relevance in aging: oxidative stress, nitric oxide, gut microbial activity, and citric acid cycle. In addition to discovering metabolites associated with longevity in Caucasians (3) such as isocitrate and aconitate, we found several functionally plausible relationships between metabolism and long-term cardiovascular outcome in African Americans. Several metabolites associated with extremes of HAI in our analysis (TMAO, hydroxyphenylacetate) have been previously implicated in intestinal metabolism, atherosclerosis development (12) , and cognitive function (13) . Higher levels of SDMA-a circulating inhibitor of NO synthase-were found in the individuals with high HAI. SDMA was also associated with an increased long-term risk of CVD-related mortality, independent of creatinine ( Table 2) . Indeed, age-related reduction in NO bioavailability is a prime mediator of vascular aging (14) , which may be specifically relevant in African Americans. Several other metabolites previously implicated in cardiometabolic risk (eg, acylcarnitines and uric acid) were also associated with HAI. Although some of these differentially expressed metabolites associated with extremes of HAI (eg, citrulline, SDMA, and acylcarnitines (15) ) are related to kidney disease, it is possible that these metabolites identify shared mechanisms of cardiovascular aging across multiple organ systems (eg, induction of endothelial dysfunction and oxidative stress with SDMA (16)), where subclinical renal dysfunction plays an important role (via excretion or production). Indeed, the association of SDMA with CVD mortality was independent of creatinine in our study population, suggesting potential importance in CVD beyond clinical measures of renal function. This result appeared to be robust to accounting for non-CVD mortality as a competing risk (Table 2) .
Recently, Murphy et al. working in the same cohort presented here demonstrated a host of metabolites associated with different aspects of body composition, including lipids, organic acids, branched-chain amino acids, tryptophan metabolites, and carnitines (4). Although several metabolites were in common with those associated with HAI (eg, kynurenic acid and C5-carnitine), there was not a significant degree of overlap in these associations. Certainly, although the role of body composition in healthy aging is well documented, this observation underlies that specificity of plasma metabolite profiling to interrogate specific, interconnected, complex aspects of aging. Larger cohorts in elderly individuals are required to address the metabolic overlap among phenotypes of aging (eg, body composition, vascular, and neurocognitive health), outcomes, and metabolism.
The conclusion of this study should be viewed in the context of its design, sample size, and pilot nature. This was a pilot study of African American males exclusively, and studies to generalize these results to a larger, multiethnic (both white and black) population across sex are necessary. Although HAI and metabolites were measured at different times (Years 1 and 2, respectively), we observed strong differences between metabolites at the extremes of HAI, suggesting the potential importance of metabolism in HAI.
In addition, direct quantification of metabolite levels (in absolute mass units) was not reported here, and future work in larger cohorts may perform these data to guide clinical decision making (prediction) rules. We used a single-value imputation method for below-detection metabolites, which may have biased us against detection of some significantly different metabolites. Nevertheless, nearly all metabolites found here were detected in all subjects in our analytic sample (Supplementary Table 1 ). Although the high event rates observed in this population (as a function of their advanced age) led us to our observation of several key associations with CVD death, larger studies with greater number of more diverse cardiovascular endpoints relevant to aging (eg, stroke) alongside competing risks analyses are necessary. In addition, standardization of biofluid used for biomarker discovery (serum vs plasma) will be important; we used plasma metabolite profiling here, limiting Those metabolites that were significantly associated with the outcome under an FDR threshold (5%) in both Models 1 and 2 were entered into Model 3. *Metabolites were associated with the outcome in multivariable regression after an FDR correction.
influences of platelet activation and effects of clotting on metabolite profile. Ultimately, larger studies are needed to assess unbiased relationships (eg, not based on HAI) between metabolic function, disability, and cardiovascular aging with adequate power across race and across sex.
In conclusion, using metabolic profiling in a group of 291 African American men, we identified a group of 19 metabolites associated with an index of healthy aging that specified known and novel pathways in aging, some of which were associated with CVD mortality. Future investigations of metabolic function are warranted to validate these results and to develop facile screening for cardiovascular aging and interventions directed at specific metabolic pathways across race.
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